X

Trial Profile

A Phase I Dose Escalation Study of NMS-03305293 in Adult Patients With Selected Advanced/Metastatic Solid Tumors

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 27 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NMS 293 (Primary) ; Temozolomide (Primary)
Indications Advanced breast cancer; Carcinoma; HER2 negative breast cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors Nerviano Medical Sciences

Most Recent Events

11 Sep 2024 Status changed from active, no longer recruiting to discontinued.
17 Apr 2024 Planned End Date changed from 30 Dec 2023 to 30 Dec 2024.
17 Apr 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com